Bivalirudin Inhibits Periprocedural Platelet Function and Tissue Factor Expression of Human Smooth Muscle Cells

Cardiovascular Therapeutics

Volumn 31, Issue 2, 2013, Pages 115-123

  Pepke, Wojciech ^a   Eisenreich, Andreas ^a   Jaster, Markus ^a   Ayral, Yunus ^a   Bobbert, Peter ^a   Mayer, Alexander ^a   Schultheiss, Heinz Peter ^a   Rauch, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anticoagulation; Bivalirudin; Heparin; PCI; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; CD63 ANTIGEN; CLOPIDOGREL; HEPARIN; HIRULOG; MESSENGER RNA; PADGEM PROTEIN; PYROPHOSPHATE; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOSPONDIN;

AGED; ARTICLE; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET MICROPARTICLE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOGENICITY; WESTERN BLOTTING;

AGED; ANTICOAGULANTS; ANTIGENS, CD63; ANTITHROMBINS; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOTTING, WESTERN; CELLS, CULTURED; CORONARY ARTERY DISEASE; FACTOR VIIA; FACTOR X; FEMALE; FLOW CYTOMETRY; GERMANY; HEPARIN; HIRUDINS; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P-SELECTIN; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STENTS; THROMBOPLASTIN; THROMBOSPONDINS; TREATMENT OUTCOME;

EID: 84875813828     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00305.x     Document Type: Article

References (40)

1. Silber S, Hoffmeister HM, Bode C. Optimal platelet inhibition after coronary stent implantation. Current status. Herz 2008;33:244-253.
2. Motovska Z, Knot J, Widimsky P. Stent thrombosis-risk assessment and prevention. Cardiovasc Ther 2010;28:e92-100.
3. Ayral Y, Rauch U, Goldin-Lang P, et al. Prolonged clopidogrel application reduces tissue factor expression after percutaneous coronary intervention in the porcine model. Cardiovasc Revasc Med 2011;12:47-55.
4. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-238.
5. Casterella PJ, Tcheng JE. Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: Practical implications, new clinical data, and recommended guideline revisions. Am Heart J 2008;155:781-790.
6. Gurm HS, Bhatt DL. Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors. Am Heart J 2005;149 Suppl:S43-S53.
7. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET. Am Heart J 2002;143:847-853.
8. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-769.
9. Lincoff AM, Bittl JA, Kleiman NS, et alREPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-1096.
10. Busch G, Steppich B, Sibbing D, et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost 2009;101:340-344.
11. Räber L, Windecker S. Current status of drug-eluting stents. Cardiovasc Ther 2011;29:176-189.
12. Eisenreich A, Celebi O, Goldin-Lang P, Schultheiss HP, Rauch U. Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel. Int Immunopharmacol 2008;8:307-311.
13. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J Clin Invest 1993;91:547-552.
14. Szotowski B, Antoniak S, Goldin-Lang P, et al. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc Res 2007;73:806-812.
15. Eisenreich A, Bogdanov VY, Zakrzewicz A, et al. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res 2009;104:589-599.
16. Eisenreich A, Boltzen U, Malz R, Schultheiss HP, Rauch U. Overexpression of alternatively spliced Tissue Factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells. Circ J 2011;75:1235-1242.
17. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat Med 2003;9:458-462.
18. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005;96:1233-1239.
19. Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease. Cardiovasc Ther 2011;29:29-36.
20. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000;96:170-175.
21. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-2315.
22. Eisenreich A, Malz R, Pepke W, Ayral Y, Poller W, Schultheiss HP, Rauch U. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. Circ J 2009;73:1746-1752.
23. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: Is sufficient cholesterol-lowering enough to inhibit plateletsvJ Am Coll Cardiol 2007;49:1035-1042.
24. Rauch U, Ziegler D, Piolot R, Schwippert B, Benthake H, Schultheiss HP, Tschoepe D. Platelet activation in diabetic cardiovascular autonomic neuropathy. Diabet Med 1999;16:848-852.
25. Piorkowski M, Weikert U, Schwimmbeck PL, Martus P, Schultheiss HP, Rauch U. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004;92:614-620.
26. Weikert U, Kühl U, Schultheiss HP, Rauch U. Platelet activation is increased in patients with cardiomyopathy: Myocardial inflammation and platelet reactivity. Platelets 2002;13:487-491.
27. Szotowski B, Goldin-Lang P, Antoniak S, et al. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy. J Am Coll Cardiol 2005;45:1081-1089.
28. Goldin-Lang P, Tran QV, Fichtner I, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 2008;20:123-128.
29. Antoniak S, Boltzen U, Eisenreich A, Stellbaum C, Poller W, Schultheiss HP, Rauch U. Regulation of cardiomyocyte full-length tissue factor expression and microparticle release under inflammatory conditions in vitro. J Thromb Haemost 2009;7:871-878.
30. Ebrahimi R, Lincoff AM, Bittl JA, et al. Bivalirudin vs heparin in percutaneous coronary intervention: A pooled analysis. J Cardiovasc Pharmacol Ther 2005;10:209-216.
31. Li G, Keenan AC, Young JC, et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol 2007;27:1850-1856.
32. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006;118:361-369.
33. Busch G, Steppich B, Sibbing D, et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost 2009;101:340-344.
34. Mehran R, Lansky AJ, Witzenbichler B, et alHORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-1159.
35. Kim JH, Jeong MH, Rhew JY, et al. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. Circ J 2005;69:159-164.
36. Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007;100:417-424.
37. Petersen LC. Microarray studies of factor VIIa-activated cancer cells. Thromb Res 2008;122 Suppl 1:S11-S13.
38. Chen X, Ren S, Ma MG, et al. Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. Atherosclerosis 2003;169:31-40.
39. Gertz SD, Fallon JT, Gallo R, et al. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries. Circulation 1998;98:580-587.
40. Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: Implications for coronary intervention. J Thromb Thrombolysis 2002;13:161-165.